186 related articles for article (PubMed ID: 26243309)
1. Aschantin targeting on the kinase domain of mammalian target of rapamycin suppresses epidermal growth factor-induced neoplastic cell transformation.
Lee CJ; Jang JH; Lee JY; Lee MH; Li Y; Ryu HW; Choi KI; Dong Z; Lee HS; Oh SR; Surh YJ; Cho YY
Carcinogenesis; 2015 Oct; 36(10):1223-34. PubMed ID: 26243309
[TBL] [Abstract][Full Text] [Related]
2. Epimagnolin targeting on an active pocket of mammalian target of rapamycin suppressed cell transformation and colony growth of lung cancer cells.
Yoo SM; Lee CJ; Kang HC; Lee HS; Lee JY; Kim KD; Kim DJ; An HJ; Cho YY
Mol Carcinog; 2019 Jul; 58(7):1221-1233. PubMed ID: 30887599
[TBL] [Abstract][Full Text] [Related]
3. The role of glycogen synthase kinase 3beta in the transformation of epidermal cells.
Ma C; Wang J; Gao Y; Gao TW; Chen G; Bower KA; Odetallah M; Ding M; Ke Z; Luo J
Cancer Res; 2007 Aug; 67(16):7756-64. PubMed ID: 17699780
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.
Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
Respir Res; 2014 Feb; 15(1):26. PubMed ID: 24571487
[TBL] [Abstract][Full Text] [Related]
5. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation.
Nomura M; He Z; Koyama I; Ma WY; Miyamoto K; Dong Z
Mol Carcinog; 2003 Sep; 38(1):25-32. PubMed ID: 12949840
[TBL] [Abstract][Full Text] [Related]
6. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
7. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
8. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
9. Fisetin regulates obesity by targeting mTORC1 signaling.
Jung CH; Kim H; Ahn J; Jeon TI; Lee DH; Ha TY
J Nutr Biochem; 2013 Aug; 24(8):1547-54. PubMed ID: 23517912
[TBL] [Abstract][Full Text] [Related]
10. Aloe emodin suppresses EGF‑induced neoplastic cell transformation by inhibiting the ERK/MSK1 and AKT/GSK3β signaling pathways.
Zhang J; Guo L; Zhang Q; Liu K; Dong Z
Mol Med Rep; 2018 Dec; 18(6):5215-5220. PubMed ID: 30272294
[TBL] [Abstract][Full Text] [Related]
11. Targeting of magnolin on ERKs inhibits Ras/ERKs/RSK2-signaling-mediated neoplastic cell transformation.
Lee CJ; Lee HS; Ryu HW; Lee MH; Lee JY; Li Y; Dong Z; Lee HK; Oh SR; Cho YY
Carcinogenesis; 2014 Feb; 35(2):432-41. PubMed ID: 24031026
[TBL] [Abstract][Full Text] [Related]
12. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
14. Mechanical regulation of glycogen synthase kinase 3β (GSK3β) in mesenchymal stem cells is dependent on Akt protein serine 473 phosphorylation via mTORC2 protein.
Case N; Thomas J; Sen B; Styner M; Xie Z; Galior K; Rubin J
J Biol Chem; 2011 Nov; 286(45):39450-6. PubMed ID: 21956113
[TBL] [Abstract][Full Text] [Related]
15. Positive correlation between overexpression of phospho-BAD with phosphorylated Akt at serine 473 but not threonine 308 in colorectal carcinoma.
Khor TO; Gul YA; Ithnin H; Seow HF
Cancer Lett; 2004 Jul; 210(2):139-50. PubMed ID: 15183529
[TBL] [Abstract][Full Text] [Related]
16. MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation.
Kim BR; Lee SH; Park MS; Seo SH; Park YM; Kwon YJ; Rho SB
Oncol Rep; 2016 Feb; 35(2):1041-8. PubMed ID: 26555156
[TBL] [Abstract][Full Text] [Related]
17. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
18. Fargesin Inhibits EGF-Induced Cell Transformation and Colon Cancer Cell Growth by Suppression of CDK2/Cyclin E Signaling Pathway.
Lee GE; Lee CJ; An HJ; Kang HC; Lee HS; Lee JY; Oh SR; Cho SJ; Kim DJ; Cho YY
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669811
[TBL] [Abstract][Full Text] [Related]
19. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
[TBL] [Abstract][Full Text] [Related]
20. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]